AC Immune's 23-Year Captain Just Left the Ship. Now What?

The marquee deal is with Takeda, signed in May 2024. Takeda paid $100 million upfront for an exclusive worldwide option on AC Immune's amyloid-beta vaccine program (ACI-24.060). If everything goes right, AC Immune could earn up to an additional $2.1 billion in milestones, plus double-digit royalties. That's a massive number for a company trading around $3 a share.

Then there's Eli Lilly, which has a collaboration on tau-targeting small molecules (the Morphomer platform). That deal is worth up to CHF 1.9 billion in potential payments, and Lilly actually expanded the partnership in 2026, a sign of growing confidence in the science. Janssen (J&J) holds a tau vaccine deal worth up to CHF 500 million. And a diagnostic partnership for a tau brain-imaging agent could generate up to EUR 160 million.

Think of AC Immune like a biotech talent agency. It scouts the talent (drug candidates), develops their early careers (Phase 1/2 trials), then signs them to major labels (pharma partners) for the big leagues. Pfeifer was the agent who built the roster.

Why the Timing Feels Loaded

Pfeifer isn't leaving during a quiet stretch. AC Immune has at least three major data readouts coming in 2026.

First, 12-month interim results from the AD3 cohort of the ABATE trial (testing the amyloid vaccine ACI-24.060 in early Alzheimer's patients) are expected in Q2 2026. This data could determine whether Takeda exercises its option, which would be a transformative event for the company.

Second, full Part 1 Phase 2 data for ACI-7104 (a Parkinson's disease vaccine targeting alpha-synuclein) should arrive in the second half of 2026. A positive readout could set up another Takeda-style mega-deal.

Third, initial Phase 1 safety data for ACI-19764, a brain-penetrating anti-inflammatory drug targeting the NLRP3 inflammasome (a key driver of brain inflammation), is also expected in late 2026.

That's a lot of plates spinning. Handing the kitchen to a new chef right now is, at minimum, bold.

The Succession Plan

Dr. Martin Zügel, the current Board Chair, will step in as interim CEO while the company conducts a formal search with an industry consultant. Pfeifer isn't vanishing entirely; she'll stay on as an advisor, honorary Board Chair, and co-chair of the Scientific Advisory Board. It's the biotech equivalent of a coach moving to the front office.

The question investors should be asking: does the next CEO continue Pfeifer's partnership-heavy, prevention-focused strategy, or pivot toward something different? AC Immune's identity is deeply tied to its founder's vision of applying cancer-style precision medicine to brain diseases. A new leader could accelerate that vision or reshape it entirely.

Wall Street Shrugs (For Now)

Analysts aren't panicking. Among the four Wall Street analysts covering AC Immune, the consensus rating is Hold, with price targets ranging from roughly $7 to $10 against a stock price hovering near $3. The most bullish target sits at $12.

The stock's biggest recent moves have been tied to pipeline news, not the CEO announcement. When the amended Lilly collaboration was disclosed, shares surged nearly 15%. The CEO retirement, by contrast, barely moved the needle. Investors seem to be saying: the science matters more than the corner office.

That calculus makes sense in the short term. AC Immune has CHF 74.8 million in cash, enough runway into late 2027. The partnerships are contractually locked in. The clinical trials keep enrolling regardless of who signs the memos.

The Bigger Picture: Tau's Moment

AC Immune's story is inseparable from the broader Alzheimer's landscape, which is shifting fast. Tau-targeted therapies have grown to account for roughly 9% of the entire Alzheimer's pipeline. The emerging consensus among researchers is that the optimal treatment will probably combine an amyloid-clearing drug, a tau-targeting agent, and an anti-inflammatory component. Think of it like a cocktail approach, similar to how HIV went from a death sentence to a manageable condition once doctors combined multiple drugs.

AC Immune is one of the few companies with assets across all three categories: an amyloid vaccine (with Takeda), tau programs (with Lilly and Janssen), and an anti-inflammatory drug (wholly owned). That positioning is rare and valuable.

But the competition is fierce. Biogen's BIIB080, an antisense drug that silences the gene responsible for tau production, showed a 60% reduction in tau biomarkers in early trials. Its Phase 2 readout is expected soon. Lilly is testing a tau antibody on top of its blockbuster amyloid drug donanemab. Roche is pushing brain-penetrating antibody technology that could reshape delivery of both amyloid and tau drugs.

AC Immune needs a leader who can navigate this increasingly crowded field while maintaining the pharma relationships Pfeifer spent two decades cultivating.

The Bottom Line

Andrea Pfeifer built AC Immune into a company that punches well above its weight. Its partnership portfolio reads like a who's who of Big Pharma, and its pipeline addresses the three pillars of Alzheimer's treatment that the field is converging on. The transition plan is orderly, and the near-term catalysts are locked in.

But founder-CEO departures in biotech are never just administrative. They change culture, strategy, and the intangible qualities that make partners trust you. The data readouts coming this year will speak for themselves. The real test is whether AC Immune can find someone who understands both the science and the relationships that make this company tick.

The ship is sturdy. The seas are promising. Now it just needs a new captain who knows where the reefs are.

The 100% Tax That Could Break Big Pharma's Global Playbook

The Trump administration just slapped a 100% tariff on every branded drug not made in America, forcing pharma companies into an impossible choice: slash prices, build U.S. factories, or watch their margins evaporate. The biggest shake-up in pharma trade policy is already reshaping the industry.